Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Canadian health care stock to report update on cough treatment study

Jonathon Brown June 6, 2023

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

GlobeNewswire June 6, 2023

Algernon completes Phase 1 DMT trial for brain injury treatment

Jonathon Brown June 5, 2023

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

GlobeNewswire June 5, 2023

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

GlobeNewswire May 31, 2023

Algernon Pharmaceuticals Announces Closing of Rights Offering

GlobeNewswire May 5, 2023

CSE Bulletin: Expiry - Algernon Pharmaceuticals Inc. - Rights (AGN.RT)

Newsfile April 21, 2023

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

GlobeNewswire April 20, 2023

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

GlobeNewswire April 17, 2023

Algernon (CSE:AGN) sees successful dosing of second cohort

Jonathon Brown April 4, 2023

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

GlobeNewswire April 4, 2023

Algernon (CSE:AGN) approved for SEC Tier II Regulation A+ US$10M offering

Trevor Abes  April 3, 2023

Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M

GlobeNewswire April 3, 2023

CSE Bulletin: New Listing - Algernon Pharmaceuticals Inc. 27APRIL2023 Rights

Newsfile March 27, 2023

Algernon (CSE:AGN) journeys toward revolutionary treatments with launch of rights offering

Research March 21, 2023

Algernon Pharmaceuticals Announces Launch of Rights Offering

GlobeNewswire March 21, 2023

Algernon (CSE:AGN) subsidiary appoints former NFL neurologist to advisory board

Trevor Abes  March 2, 2023

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

GlobeNewswire March 2, 2023

Algernon Pharmaceuticals (CSE:AGN) announces stock split

John Ballem  March 1, 2023

CSE Bulletin: Stock Split - Algernon Pharmaceuticals Inc. (AGN)

Newsfile March 1, 2023